Patients with psoriatic arthritis (PsA) who had inadequate responses or intolerance to tumor necrosis factor (TNF) inhibitors showed significant improvements in clinical and patient-reported outcomes (PROs) after initiating upadacitinib, an oral Janus kinase (JAK) inhibitor, according to real-world data from the OM1 PsA registry presented at the American College of Rheumatology Meeting in Washington, DC.

Alexis Ogdie, MD, on behalf of herself and colleagues from AbbVie and the OM1 team, presented findings of a study that assessed upadacitinib’s real-world effectiveness in PsA patients previously treated with TNF inhibitors. The study aimed to evaluate improvements in key outcomes following the initiation of upadacitinib among this patient group.

Dr Ogdie is director of the Penn Psoriatic Arthritis and Spondyloarthritis Program at the University of Pennsylvania in Philadelphia, Pennsylvania.

Using the OM1 PsA Registry, which tracks over 60,000 PsA patients managed by rheumatologists, the study included TNF inhibitor-experienced adults (≥18 years) who began upadacitinib on or after December 14, 2021. Inclusion criteria required at least 6 months of data prior to upadacitinib initiation and follow-up outcome measures at 3 or 6 months post-index.

Clinical and PRO measures were assessed, including RAPID3, Tender Joint Count28, (TJC28) Swollen Joint Count28 (SJC28), pain, fatigue, and health assessments using the Multi-Dimensional Health Assessment Questionnaire (MDHAQ). Paired t-tests compared baseline scores to those at 3- and 6-month follow-ups.

A total of 535 patients were included in the analysis, with a mean age of 55.2 years; 73% were female and 95% were White. At baseline, the mean scores for clinical outcomes and PROs were: RAPID3 (4.45), TJC28 (5.97), SJC28 (3.13), pain (5.71), fatigue (5.95), MDHAQ Physician Global Assessment (3.54), and MDHAQ Patient Global Assessment (5.21).

At 3 months after upadacitinib initiation, patients experienced significant improvements across all outcomes (P < 0.05), including reductions in RAPID3 (-0.44), TJC28 (-1.82), SJC28 (-0.97), pain (-0.85), fatigue (-0.73), MDHAQ Physician Global Assessment (-0.72), and MDHAQ Patient Global Assessment (-0.53). These improvements were maintained at 6 months.

The investigators concluded that upadacitinib is effective in improving joint symptoms, pain, fatigue, and overall health in real-world PsA patients with prior TNF inhibitor treatment, supporting its use in clinical practice for this patient population.

Reference:

Ogdie A, Ye X, Peng Y, et al. 0586: Real-world effectiveness of upadacitinib in patients with psoriatic arthritis previously treated with TNF inhibitors: data from the OM1 registry. Presented at: American College of Rheumatology. November 14–19, 2024. Washington, DC.